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Abstract Wilson disease is a genetic disorder of copper
metabolism characterized by the toxic accumulation of copper
in the liver. The ATP7B gene, which encodes a copper
transporting P-type ATPase, is defective in patients with Wilson
disease. To investigate the function of ATP7B, wild type or
mutated ATP7B cDNA was introduced into a yeast strain
lacking the CCC2 gene (vccc2), the yeast homologue of ATP7B.
Wild type and the H1069Q mutant could rescue vccc2, however,
the N1270S mutant could not, reflecting phenotypic variability of
Wilson disease. In addition, the mutant containing only the sixth
copper binding domain could rescue vccc2, indicating its
functional importance.
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1. Introduction
Copper is an essential trace metal for prokaryotes and eu-
karyotes, and is a required component for a variety of en-
zymes, including cytochrome oxidase and other copper con-
taining enzymes [1,2]. However, excess accumulation of
copper ion in the body is toxic, because it acts predominantly
through the formation of highly reactive hydroxyl radicals,
which lead to damage of cell membranes, mitochondria, pro-
teins and DNA [3].
Wilson disease is an autosomal recessive disorder of copper
transport and has a worldwide frequency of between one in
35 000 and one in 100 000 live births [4]. The disorder mani-
fests as chronic liver disease and/or neurological impairment,
frequently with kidney malfunction, due to toxic accumula-
tion of copper in several tissues, principally the liver, brain
and kidney. This disease is believed to be caused by the mu-
tation of the gene which encodes a copper transporting P-type
ATPase (ATP7B) [5^7] and various mutations in this gene
have been reported in patients with Wilson disease [7^9].
The excessive accumulation of copper in a¡ected liver is
thought to be due to reduced biliary excretion of copper
and disturbed incorporation of copper into ceruloplasmin
(CPN) [10].
P-type ATPases, de¢ned as those forming a covalent phos-
phorylated intermediate in their reaction cycle, transport a
variety of cations across membranes [11]. The general features
of those include the TGEA/S motif (phosphatase domain), the
DKTGT/S motif (phosphorylation domain), the TGDN motif
(ATP-binding domain), and the sequence MXGDGXNDXP
that connects the ATP binding domain to the transmembrane
segment. ATP7B protein is further classi¢ed as a heavy metal
transporting P-type ATPase which pumps copper or cadmium
[12^14]. The six repeated motifs, GMTCXXC, at the N-ter-
minus of ATP7B are thought to be copper binding domains
from their homology with CopA, a copper transporting ATP-
ase in copper resistant strains of Enterococcus hirae [15]. A
recent study has demonstrated that this motif has speci¢city
for copper and 6 mol of copper bind to 1 mol of N-terminus
of ATP7B [16]. ATP7B also contains the SEHPL and CPC
motifs, conserved in heavy metal transporting ATPases and
involved in heavy metal translocation [12^14].
The yeast CCC2 gene, homologous to the human Wilson
and Menkes genes, has been shown to encode a copper trans-
porting P-type ATPase with two copies of the conserved cop-
per binding motif [17]. Fet3 protein (Fet3p, multi-copper ox-
idase), known as a membrane bound CPN-like protein in
yeast, is required for ferrous transport, indispensable for yeast
growth [18,19]. The copper binding to Fet3p is necessary to
manifest its oxidase activity and this process is mediated by
Ccc2p [17]. Thus, Ccc2p is involved in high a⁄nity iron up-
take. On the other hand, vccc2, the yeast mutant strain lack-
ing CCC2, can survive in an iron rich environment, suggesting
the existence of an alternative pathway for iron transport into
cells. Our recent report has demonstrated that Ccc2p function
is complemented by the introduction of cua-1 cDNA, encod-
ing a copper transporter of Caenorhabditis elegans, into the
vccc2 strain [20].
In this study, we constructed several mutated cDNAs re-
ported in Wilson disease patients as well as deleted cDNAs
within the copper binding domains of ATP7B, and introduced
these cDNAs into the yeast vccc2 strain to investigate their
functions.
2. Materials and methods
2.1. Construction of mutated ATP7B cDNAs
Full length ATP7B cDNA was constructed as described previously
[21]. To obtain deleted cDNAs within copper binding domains, the
full length ATP7B cDNA was digested with restriction enzymes as
indicated in Fig. 1A. As shown in Fig. 1A, Cu0 has the deletion of
ATP7B cDNA from nucleotides (nt) 320 to 1991. Cu1^2, from nt 811
to 1991. Cu1^3, from nt 1132 to 1991. Cu1^4, from nt 1489 to 1991.
Cu1^5, from nt 1781 to 1991. Cu6, from nt 320 to 1804. To introduce
point mutations into ATP7B cDNA (Fig. 1B), site directed mutagen-
esis using the polymerase chain reaction (PCR) was performed [22]. A
HincII-SacI fragment (nt 2795^3762) containing the DKTG motif and
the SEHPL motif and a SacI-PvuII fragment (nt 3762^4729) contain-
ing the GDGVND motif were cloned into vector pUC18 and used as
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templates for PCR. Primers used for D1027A were 5P-ACTGTGAT-
GTTTGCCAAGACT-3P, for T1029A, 5P-TTTGACAAAGGCTGG-
CACCATT-3P, for H1069Q, 5P-AGTGAACAACCCTTGGGCGT-3P,
and for N1270S, 5P-CGGGGAGTCACTGACCCCAT-3P. MUT1 pri-
mer, 5P-CATGATTACGAGTTCTAGCT-3P (Takara, Kyoto, Japan),
was used as a counterpart for each primer. The presence of the speci¢c
mutations or deletions, as well as the ¢delity of the entire cDNA
sequence, were con¢rmed by using Abi Prism Dye terminator cycle
sequencing ready reaction kit (Perkin-Elmer).
To detect the expression of the above cDNAs, the hemagglutinin
(HA) epitope (Boehringer Mannheim) was inserted into each con-
structed cDNA at the Eco47III site, corresponding to nt 4327 in
wild type ATP7B cDNA. All of the constructed cDNAs were inserted
into the mammalian expression vector pRC/CMV (Invitrogen) and
the yeast expression vector pSY114 [20].
2.2. Yeast strains, growth conditions, and transformations
The CCC2 gene was disrupted from chromosomal DNA of Saccha-
romyces cerevisiae YPH499 (MATa, ura3-52, leu2-v1, trp1-v63, his3-
v200, ade2-101, lys2-801) [20]. vccc2 yeast cells were transformed with
the constructed cDNAs by the modi¢ed lithium acetate method [20],
and the transformants were selected on solid synthetic dextrose (SD)
medium (0.67% yeast nitrogen base without amino acids, 2% glucose,
2% agar) supplemented with adenine, uracil, tryptophan, and lysine
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Fig. 1. Construction of mutated ATP7B cDNA. A: Each ATP7B cDNA with a deletion in copper binding domains was constructed by cleav-
ing the full length ATP7B with indicated restriction enzymes. B: Point mutated ATP7B cDNAs were produced by site directed mutagenesis
with the oligonucleotide primers, described in Section 2. Asp1027Ala (D1027A) and Thr1029Ala (T1029A) are point mutated in the phospha-
tase domain. His1069Gln (H1069Q) in the SEHPL motif, highly conserved in heavy metal transporting ATPases. Asn1270Ser (N1270S) in the
hinge domain. Each constructed cDNA was inserted into the expression vectors for mammalian and yeast.
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[20]. For metal dependent tests, histidine (20 mg/ml) and leucine (60
mg/ml) were added to the same medium with 2% agar instead of 0.7%
agarose (test medium). The selected transformants were grown at
30‡C for 4 days on the test medium containing 500 WM of bathocu-
proine disulfonate and/or 500 WM ferrozine (3-(2-pyridyl)-5,6-bis(4-
phenylsulfonic acid)-1,2,4-triazine), or nothing.
2.3. Protein extraction from the yeast and immunoblotting
2U107 yeast cells were suspended in 1 ml of 1 M sorbitol contain-
ing 0.2 N NaOH and 8% 2-mercaptoethanol, and incubated on ice for
10 min. Subsequently, 100 Wl of 30% trichloroacetic acid was added
and protein was precipitated on ice for 10 min. Protein was collected
by centrifugation at 12 000 rpm for 10 min, washed with ice cold
acetone twice, and then dissolved in 50 Wl of SDS sample bu¡er
(62.5 mM Tris-HCl, 0.01% phenol red, 10% glycerol, 40 mM dithio-
threitol, 5% sodium dodecyl sulfate). 25 Wl of protein samples was
resolved by polyacrylamide gel electrophoresis (PAGE), and immuno-
detection was performed as described [21].
3. Results
To obtain deleted cDNAs within copper binding domains,
the full length ATP7B cDNA was digested with restriction
enzymes as indicated in Fig. 1A. These mutants lack the in-
dicated copper binding domains. Site directed mutagenesis
was applied to produce the mutants D1027A, T1029A,
H1069Q, and N1270S, as described above (Fig. 1B). The mu-
tations of D1027A and T1029A, located in the DKTG motif,
lead to the disruption of phosphorylation of the motif.
H1069Q in the SEHPL motif and N1270S in the hinge do-
main may a¡ect heavy metal translocation and hinge region,
respectively.
Since our previous reports conducted by in vitro and in
vivo studies [21,23] have revealed that the wild type ATP7B
protein localizes to the Golgi apparatus, we examined the
localization of the mutated ATP7B proteins by the introduc-
tion of mutated cDNAs into COS1 cells. The immuno£uo-
rescence study showed that the products of wild type and
mutated cDNAs except Cu1^5 are detected in the perinuclear
region in transfected COS1 cells, indicating the mutated
ATP7B proteins mainly reside in the Golgi apparatus (data
not shown). However, the product of the Cu1^5 mutant
mainly showed a di¡used staining in the whole cytoplasm
(data not shown), implying that the deletion surrounding
the sixth copper binding domain of ATP7B protein may
lead to missorting of the protein.
To con¢rm the expression of mutated ATP7B proteins in
the vccc2 yeast strain, we performed Western blot analysis
using cell homogenates prepared from the vccc2 strains trans-
fected with mutated ATP7B cDNAs. The molecular masses of
mutants with deletion in copper binding domains, such as
Cu0, Cu1^2, Cu1^3, Cu1^4, Cu1^5, and Cu6, were 120
kDa, 135 kDa, 155 kDa, 160 kDa, 170 kDa, and 125 kDa,
respectively (Fig. 2A, lanes 3^8), consistent with the molecular
masses deduced from the amino acid sequences. However, the
level of expression of Cu1^5 (Fig. 2A, lane 7) was signi¢cantly
low compared with those of other deleted mutants. This is
probably due to the degradation of translated protein resulted
from missorting of the protein as suggested above, since
Southern blot and Northern blot analyses revealed that the
amount of transfected DNAs and the resulting mRNA expres-
sion were equivalent (data not shown). In addition, the mo-
lecular masses of mutated ATP7B proteins with a single ami-
no acid substitution, such as D1027A, T1029A, H1069Q, and
N1270S, were identical with that of the wild type ATP7B
protein and their expression was equivalent with the wild
type (Fig. 2B, lanes 10^14).
We then transfected mutated ATP7B cDNAs into the vccc2
strain to investigate their function with respect to the growth
of vccc2 under various metal concentrations. As shown in
Fig. 3A, all of the transfected vccc2 strains were able to
grow on an SD medium which contained su⁄cient iron and
copper. Additionally, no growth impairment was observed in
each vccc2 strain on an SD medium supplemented with a
copper chelator, bathocuproine disulfonate (Fig. 3B), indicat-
ing iron was taken up from the environment through the low
a⁄nity uptake pathway. In contrast, the vccc2 strains which
could grow in a medium containing the iron chelator ferrozine
were only those transfected with wild type ATP7B, Cu6, or
H1069Q cDNAs (Fig. 3C). However, the growth of vccc2
with H1069Q (Fig. 3C, area 13) was slower than that of
vccc2 rescued by wild type ATP7B and Cu6 (Fig. 3C, areas
4 and 10). In addition, vccc2 with H1069Q could not grow in
a medium containing less copper (data not shown). None of
the transfected vccc2 strains could grow on medium supple-
mented with both chelators (Fig. 3D). These results suggest
that products of wild type ATP7B, Cu6, or H1069Q cDNA
recover iron uptake in a copper dependent manner and com-
plement the function of Ccc2p.
4. Discussion
In this study we demonstrated that human ATP7B protein
was able to rescue the yeast vccc2 mutant. In addition, the
Cu6 mutant bearing the sixth copper binding domain and the
H1069Q mutant, the most common mutation reported in Wil-
son disease patients [7^9], were also found to restore the func-
tion of yeast Ccc2p.
A previous report demonstrated that the yeast CCC2 gene
encoded copper transporting P-type ATPase and was a yeast
counterpart for human ATP7A or ATP7B, defective in
Menkes disease or Wilson disease, respectively [17]. This re-
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Fig. 2. Detection of wild type and mutant ATP7B proteins in the
vccc2 strain of yeast. Western blot showing the chemiluminescent
detection of ATP7B proteins lacking the copper binding domains
(A) and point mutated ATP7B proteins (B) in the transformed
vccc2. Total protein was extracted from 2U107 cells of each trans-
formant, applied to 7% SDS-PAGE, and transferred to a PVDF
membrane. The blots were probed with mouse anti-HA monoclonal
antibody (1:50) followed by horseradish peroxidase conjugated anti-
mouse IgG (1:4000). Bound antibody was detected by enhanced
chemiluminescence. A: Lane 1, vector alone; lane 2, wild type
ATP7B; lane 3, Cu0; lane 4, Cu1^2; lane 5, Cu1^3; lane 6, Cu1^4;
lane 7, Cu1^5; lane 8, Cu6. B: Lane 9, vector alone; lane 10, wild
type ATP7B; lane 11, D1027A; lane 12, T1029A; lane 13, H1069Q;
lane 14, N1270S.
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port also revealed that Ccc2p was required for the oxidase
activity of Fet3p and the high a⁄nity iron uptake [17]. The
yeast vccc2 mutant lacking the CCC2 gene is not able to grow
in iron-de¢cient medium due to the reduced uptake of iron
resulting from the disturbed incorporation of copper into
Fet3p. However, the vccc2 mutant was rescued by expression
of human ATP7B protein in a copper dependent manner (Fig.
3), indicating that ATP7B protein complements Ccc2p func-
tion. This notion is supported by recent reports that introduc-
tion of C. elegans cua-1 cDNA, homologous to ATP7A/
ATP7B, rescued the vccc2 mutant [20], and that expression
of ATP7B protein in the vccc2 mutant restored copper incor-
poration into Fet3p [24].
To examine how the products of mutated ATP7B genes,
reported in Wilson disease patients, manifest their function,
the vccc2 strain was transformed with the H1069Q mutant,
the N1270S mutant, and the Cu1^5 mutant lacking the sixth
copper binding domain. H1069Q is the most common muta-
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Fig. 3. Metal dependent test for the growth of the yeast vccc2 strain transformed with wild type and mutated ATP7B cDNAs. The vccc2 yeast
cells were transformed with the mutated ATP7B cDNAs and the transformants were selected on solid synthetic dextrose (SD) medium as de-
scribed in Section 2. The transformed cells were grown at 30‡C for 4 days on SD medium containing metal ion chelators. Plate A, no chela-
tors; plate B, 500 WM bathocuproine disulfonate for chelating copper; plate C, 500 WM ferrozine for chelating iron; plate D, 500 WM bathocu-
proine disulfonate and 500 WM ferrozine. Strains grown on each plate are YPH499 (wild type strain, area 1), vccc2 (area 2), vccc2 transformed
with vector alone (area 3), vccc2 with wild type ATP7B (area 4), vccc2 with Cu0 (area 5), vccc2 with Cu1^2 (area 7), vccc2 with Cu1^4 (area
8), vccc2 with Cu1^5 (area 9), vccc2 with Cu6 (area 10), vccc2 with D1027A (area 11), vccc2 with T1029A (area 12), vccc2 with H1069Q
(area 13), and vccc2 with N1270S (area 14).
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tion in the patients, representing approximately 38% of sam-
ples studied by Shah et al. [9]. This mutation, located in the
SEHPL motif, may impair heavy metal translocation across
membranes [13,14]. The partial restoration of Ccc2p function
by mutant H1069Q in the vccc2 strain (Fig. 3) may in part
explain the variable clinical manifestation in patients with this
mutation [9]. By contrast, the N1270S mutation, located in
the hinge domain and found predominantly in patients from
Costa Rica [9], was not able to rescue the vccc2 mutant (Fig.
3). This result may correlate with a high incidence of the
fulminant type of the disease in those samples [9]. Cu1^5
mutant lacking the sixth copper binding domain of ATP7B
protein, mimicking the mutation with skipping exon 5 [8], also
failed to restore the Ccc2p function (Fig. 3). However, this is
probably because of inadequate expression of this mutant.
Taken together, the variety of phenotypic manifestation of
the disease mutation studied in this report may imply that
epigenetic or environmental factors, other than genetic factor,
in£uence the phenotypic outcome among Wilson disease pa-
tients. In addition, we introduced single amino acid substitu-
tions in the DKTG motif, such as D1027A and T1029A, to
produce missense mutations, since an aspartic acid residue in
this motif is thought to be phosphorylated. Both mutants
could not rescue the vccc2 mutant, suggesting the DKTG
motif is essential for the manifestation of ATP7B function.
Copper transporting P-type ATPases identi¢ed in various
species show di¡erences in the number of metal binding mo-
tifs, which are six in ATP7B, ¢ve in Atp7b (the rat homo-
logue) [25], three in Cua-1 of C. elegans [20], two in Ccc2p
[17], and one in CopA of E. hirae [15]. Thus, to evaluate the
necessity of six domains for copper binding, various deleted
mutants within these domains were constructed and trans-
fected into the vccc2 mutant. Consequently, while none of
the mutants lacking the sixth copper binding domain could
not rescue the vccc2, the Cu6 mutant bearing only the sixth
copper binding domain complemented Ccc2p function (Fig.
3). This result indicates that the sixth copper binding domain
is necessary to manifest the function of ATP7B protein and
that the copper binding domains are not functionally equiv-
alent. A recent report has shown that the third copper binding
domain in ATP7A is critical for copper transport [26]. This
discordance with our current data is probably due to the
di¡erences in construction of mutated DNA. In this study
we deleted the copper binding domains of ATP7B, while ami-
no acid substitutions were introduced into the copper binding
domains of ATP7A in the other report. This may lead to a
conformational alteration of the proteins responsible for their
function. The importance of the sixth copper domain in
ATP7B is probably supported by the evidence that CopA
has only one copper binding domain. However, questions
on how the ¢ve other domains associate with the function
of ATP7B with respect to copper transport still remain.
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